Joint development agreement will accelerate NDA filing and worldwide commercialisation of certain products in CutisPharma's R&D portfolio
Dr. Reddy's Laboratories has agreed a joint Active Pharmaceutical Ingredient (API) supply and development agreement with speciality pharmaceutical firm CutisPharma to advance several programmes in CutisPharma's R&D portfolio.
CutisPharma, based in Wilmington, MA in the US, is a privately held company focusing on the development and commercialisation of value-added proprietary pharmaceutical products and technologies in the prescription compounding sector of the healthcare industry. Its product line and development efforts are focused on providing more efficient alternatives for the preparation of compounded prescriptions, by offering FIRST Unit-of-Use Prescription Compounding Kits.
'This partnership has significant strategic benefits for both parties,' said Neal Muni, Chief Executive of CutisPharma.
'Dr. Reddy's Laboratories' breadth of expertise and international infrastructure provide great synergy to CutisPharma's own R&D and commercial organisations and will be a significant catalyst in our plans to fast-track the development of three of our programmes towards New Drug Application (NDA) filings.'
CutisPharma has recently opened a state-of-the-art manufacturing centre at its Wilmington facility and has completed validation activities supporting its first NDA filing of the company's lead pipeline drug, RM-01, next year.
The partnership with Dr. Reddy's Laboratories will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval.